Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Resmetirom Clear all
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 1 Interventional

Resmetirom in Patients With MASH and HFpEF

NCT07830758
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Peoria, Arizona • Oxnard, California • Fort Myers, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 4 Interventional

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

NCT07848191
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Rezdiffra, Resmetirom, ACTOS/pioglitazone, FARXIGA/dapagliflozin
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Chandler, Arizona • North Little Rock, Arkansas • Coronado, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

NCT07216313
View directory record Official record
Conditions
Healthy
Interventions
Denifanstat, Resmetirom
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Atorvastatin

NCT02749578
View directory record Official record
Conditions
Healthy
Interventions
Atorvastatin, MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 16, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222
View directory record Official record
Conditions
NASH, Cirrhosis, Liver
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

NCT04197479
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Placebo, Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
76
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

NCT03220165
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects

NCT01367873
View directory record Official record
Conditions
Drug Safety
Interventions
Placebo, VIA-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

NCT03413124
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196 Tablet, MGL-3196 Capsule
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 16, 2026, 10:08 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy

NCT07860814
View directory record Official record
Conditions
Metabolic Dysfunction-steatohepatitis (MASH)
Interventions
Not listed
Lead sponsor
Radnet Management, Inc.
Network
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Houston, Texas • Pearland, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Not yet recruiting Phase 4 Interventional

Nutrition Intervention Combined With Resmetirom for MASH

NCT07680478
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Resmetirom therapy, Comprehensive nutritional intervention, Standard dietary support
Drug · Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal Function

NCT06397872
View directory record Official record
Conditions
Renal Impairment
Interventions
100 mg Resmetirom Tablet
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rezdiffra Pregnancy and Lactation Registry

NCT07541469
View directory record Official record
Conditions
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Rezdiffra
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
West Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

NCT07143968
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions
Resmetirom, Placebo Control
Drug
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Clopidogrel

NCT04671069
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Clopidogrel
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Study of Resmetirom in Children and Adolescents With MASH

NCT07763015
View directory record Official record
Conditions
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT02912260
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
MGL-3196, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Dothan, Alabama • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

NCT02542969
View directory record Official record
Conditions
Healthy
Interventions
Simvastatin, Rosuvastatin, MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects

NCT04643795
View directory record Official record
Conditions
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
Interventions
MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 16, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

NCT03900429
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MGL-3196, Placebo, Liver Biopsy
Drug · Procedure
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
90
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 16, 2026, 10:08 PM EDT